Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6712597 | 1.00 | GAA (0.46) | GAAMAPTALDH1A1POLBKDM4E | |
| SCHEMBL1444580 | 0.66 | POLB (0.52) | GAAMAPTALDH1A1POLBKDM4E | |
| SCHEMBL11900792 | 0.65 | PIK3CD (0.48) | MAPTPOLBKDM4EMAPK1L3MBTL1 | |
| SCHEMBL6712598 | 0.63 | MAPT (1.00) | GAAMAPTALDH1A1POLBKDM4E | |
| SCHEMBL2805776 | 0.62 | CASP1 (0.50) | GAAMAPTALDH1A1POLBKDM4E | |
| SCHEMBL1975340 | 0.61 | HRH1 (0.70) | MAPTALDH1A1KDM4ELMNAMAPK1 | |
| SCHEMBL7296560 | 0.60 | TERT (0.48) | GAAMAPTALDH1A1POLBKDM4E | |
| SCHEMBL11208162 | 0.59 | SMN1; SMN2 (0.71) | MAPTALDH1A1KDM4ELMNAMAPK1 | |
| Bromide SCHEMBL7294983 | 0.58 | TERT (0.47) | GAAMAPTALDH1A1POLBKDM4E | |
| SCHEMBL10804218 | 0.58 | ALDH1A1 (0.50) | GAAMAPTALDH1A1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053977-A1 | Medicinal uses of hydrazones | ALMSTEAD JI-IN KIM (US) | 2004-03-18 | — | — | US | claimed |
| US-6660737-B2 | Antihypoxic agents | THE PROCTER & GAMBLE COMPANY | 2003-12-09 | — | — | US | claimed |
| US-20030092716-A1 | Medicinal uses of hydrazones | THE PROCTER & GAMBLE COMPANY | 2003-05-15 | — | — | US | claimed |
| US-20040053977-A1 | Medicinal uses of hydrazones | ALMSTEAD JI-IN KIM (US) | 2004-03-18 | — | — | US | disclosed |
| US-6660737-B2 | Antihypoxic agents | THE PROCTER & GAMBLE COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-20030092716-A1 | Medicinal uses of hydrazones | THE PROCTER & GAMBLE COMPANY | 2003-05-15 | — | — | US | disclosed |
| WO-2002089809-A1 | MEDICINAL USES OF HYDRAZONES AND HYDRAZINES | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053977-A1 | Medicinal uses of hydrazones | PGF, VEGFA, TEK | GAA 1089/4885MAPT 4168/4885ALDH1A1 80/4885 |
| US-20030092716-A1 | Medicinal uses of hydrazones | EPOR, VEGFA, HIF1A | GAA 635/4885MAPT 4120/4885ALDH1A1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.